Benefits Of Respiratory Combination Vaccines Spur Rapid Adoption By Beef And Dairy Producers
Millsboro, DE - The benefits of complete respiratory disease protection, vaccination convenience and Beef Quality Assurance (BQA)–friendly attributes has led to a surge in demand by beef and dairy producers for modified-live virus (MLV) pasteurella combination vaccines.
An independent market-research firm that focuses on veterinary products' market share and product sales tracking has measured a dramatic increase in the MLV pasteurella combination vaccine category.
According to Market Dynamics Inc., the MLV pasteurella combination vaccine category has grown more than 60 percent from 2001 to 2006 in the United States. These MLV respiratory pasteurella combination products now represent a $20M-plus vaccine category that includes products like Intervet's Vista Once SQ, which offers a unique avirulent live Pasteurella multocida and Mannheimia haemolytica and five-way viral combination in a single, subcutaneous dose.
"Launched in late 2005, Vista Once SQ captured the No. 1 position in the MLV pasteurella combination vaccine category in its first year," says Jeff Baxter, Intervet marketing manager for cattle vaccines. "Vista Once SQ currently maintains an industry-leading position with 47 percent of the category market share. Producers and veterinarians appreciate the advantage of getting the most complete protection with the convenience of one injection, while consumers benefit with the BQA benefits of a single, one-time subcutaneous injection. It's a win-win."
Producing quality beef
Another reason for the rapid adoption of these combination vaccines is the increasing awareness of and compliance with BQA recommendations, Baxter says. The combination vaccine eliminates the need for administering an additional injection, which reduces stress on the animal and benefits meat quality.
MLV Combination Vaccine Growth / Add One
"The rapid acceptance of Vista combination vaccines is evidence of the market's growing implementation of BQA-recommendations and call for greater convenience," says Scott Nordstrom, D.V.M., and Intervet Veterinary Services Manager. "Producers want their calves to have the broadest protection possible with the fewest injections. They also want to assure quality so the consumer gets an enjoyable eating experience every time he or she enjoys a meal containing beef."
Nordstrom reminds producers and veterinarians of the importance of sub-Q vaccine administration, stating that injection-site lesions continue to cost the industry millions of dollars each year.
He says, "The National Cattlemen's Beef Association's BQA guidelines encourage beef producers to use cattle vaccines, like Vista, that are administered subcutaneously to help eliminate costly damage to the end beef product caused by products administered intramuscularly."
Most complete, long-lasting respiratory protection Vista Once SQ is the only one-dose, modified live viral combination vaccine with avirulent live protection against Mannheimia haemolytica and Pasteurella multocida. The vaccine is labeled for the vaccination of healthy cattle as an aid in the prevention of respiratory disease caused by infectious bovine rhinotracheitis (IBR) virus; bovine virus diarrhea (BVD Type 2); bovine respiratory syncytial virus (BRSV); and as an aid in the control of disease caused by BVD Type 1, parainfluenza3 virus (PI3), Mannheimia haemolytica and Pasteurella multocida. Respiratory duration of immunity has been demonstrated to be at least 182 days for IBR, at least 206 days for BVD Type 1 and at least 200 days for BVD Type 2.
Producers looking for the convenience of a combination vaccine that provides the most complete protection from costly respiratory diseases and is BQA-compliant should ask their veterinarians or animal-health suppliers for more information about Vista Once SQ.
SOURCE: Market Dynamics Inc.